Cognate BioServices is a contract development and manufacturing organization specializing in cell and gene-mediated cell therapy. The company has supported the development of FDA-approved therapies and conducted numerous studies in this field.

Cognate BioServices

Ascendant Group Branding is a CEO branding development firm specializing in corporate brand strategy and development for CEO and executive leaders. The company focuses on brand monetization, brand acceleration, and brand strategy, utilizing a proprietary five-phase branding system.

Ascendant Group Branding

CellCarta is a global contract research organization providing testing services including biomarker solutions, immune monitoring, proteomics, genomics, histopathology, and regulatory expertise. This description is self-described as the company offers advanced scientific capabilities to support therapeutic development.

CellCarta

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Impel Pharmaceuticals Inc.

Biotechnology Research

Charles River Laboratories

Cognate BioServices, a Charles River Company | 12,705 followers on LinkedIn. Your CDMO Partner from Concept to Commercial for Cell &amp; Gene Therapy Products | Cognate BioServices is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. We pride ourselves in the level of quality and experience we bring to the table. 
Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions.

Metric
Company Name	Cognate BioServices	Ascendant Group Branding	CellCarta	Impel Pharmaceuticals Inc.
Symbol				IMPL
MSH ID	COM:COGNATEBIOSERVICES	COM:ASCENDANTGROUPBRANDING	COM:CELLCARTA	COM:IMPELPHARMA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Commercial & Professional Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Marketing & Advertising	Contract Research Organization	Biotechnology
Country	US	US	US	US
Stage	Series B			Debt
Employee Count				160
Website	cognatebioservices.com	ascendantgroupbranding.com	cellcarta.com	impelpharma.com
LinkedIn	cognate-bioservices		cellcarta	impel-pharma
Founders

Metric
Market Cap				956K
Enterprise Value
Monthly Web Traffic				324
Web Traffic Growth				-0.20
Valuation
Raised Capital				50M

Metric
Revenue				12.65M
Revenue (LTM)
Revenue (NTM)
Gross Profit				6.16M
EBITDA				-83.18M
Operating Income				-83.18M
Net Income				-129.44M
EPS				-5.52
Diluted EPS				-5.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.53
Operating Profit Margin				-3.34
EBITDA Margin				-6.57
Net Profit Margin				-4.58
Return on Equity				1.33
Return on Assets				-2.74
Return on Capital Employed				0.78

COGN

COM:COGNATEBIOSERVICES

Cognate BioServices

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-0.01
P/B Ratio				-0.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				0.05
EV Multiple				1.66

Metric
Days Sales Outstanding				114.65
Days Payables Outstanding				136.95
Days Inventory Outstanding				251.74
Operating Cycle				366.39
Cash Conversion Cycle				229.44
Asset Turnover				0.60

Metric
Operating Cash Flow				-93.64M
Free Cash Flow				-95.02M
Cash Flow to Debt				-0.69
Operating Cash Flow/Sales				-3.77
Free Cash Flow Yield				-85.75

Metric
Cash & Equivalents				60.65M
Accounts Receivable				-6.09M
Inventory				8.43M
Goodwill
Debt to Capitalization				5.01
Debt to Assets				3.27
Current Ratio				0.19
Quick Ratio				0.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.23
R&D to Revenue				0.20
SG&A to Revenue				3.67